Artiklar
BRIGHT publication
The Bright study demonstrated similar efficacy and safety of Toujeo® (Glargine 300) compared to degludec (insulin degludec) in type 2 diabetes patients who had not previously received basal insulin1.
DELIVER-G: Real-world analysis in insulin-naïve adults with T2DM on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†1
DELIVER-G: Real-world analysis in insulin-naïve adults with T2DM on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†1
The RESTORE-G Real World Evidence Study
RESTORE-G: Real-world analysis in insulin-naïve adults with T2D on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†2
Diabetes och träning
På den här sidan kan du lära dig mer om diabetes och träning, både vid typ 1 och typ 2.
Diabetes och Ramadan
2025 infaller Ramadan mellan 28 februari och 29 mars. Vi har tagit fram material för att hjälpa dig att stötta din patient med diabetes som vill fasta under Ramadan.
Glycaemic Targets and Vascular Complications in Type 2 Diabetes: What Are the Thresholds?
Summary of Zoungas S, et al. Diabetologia. 2012;55:636–643.
